Stanley T. Crooke, M.D., Ph.D., Founder, Chairman and CEO of n-Lorem, Presented with the 2022 Steven C. Beering Award

September 8, 2023

n-Lorem founder, chairman, and CEO, Stanley T. Crooke, M.D., Ph.D. was presented with the 2022 Steven C. Beering Award from Indiana University School of Medicine

n-Lorem founder and CEO, Stanley Crooke, M.D., Ph.D., has been awarded the 2022 Steven C. Beering Award.  This award recognizes Dr. Crooke’s seminal work in pioneering a new drug discovery platform that harnesses the power of antisense oligonucleotides (ASOs) to target genetic disorders and the field-changing implications that Dr. Crooke’s outstanding work has had, and will continue to have, in biomedical sciences. 

The Steven C. Beering Award is given by Indiana University School of Medicine to one person each year. It honors an internationally recognized individual for outstanding research contributions to advancing biomedical or clinical science. In selecting Dr. Crooke for the award, the committee recognizes Dr. Crooke’s lifetime dedication in creating and advancing ASO technology to alter the expression of genes and ultimately disease-causing proteins.  It is through the efforts led by Dr. Crooke that ASO technology is now a highly regarded, validated, versatile and efficient drug discovery platform that has, and will continue to change, the landscape of untreatable diseases. Past winners of this prestigious award include Dr. George Church, Dr. William Kaelin, and Dr. George Stark.

Congratulations, Dr. Crooke!

Press Releases

n-Lorem Foundation Founder and CEO, Stanley Crooke, M.D., Ph.D., Awarded the Steven C. Beering Award

We cannot do
this alone

Together we are changing the world—
one patient at a time

We hope that you join us on this journey to discover, develop and provide individualized antisense medicines for free for life for nano-rare patients. The ultimate personalized medicine approach – for free, for life.

We need your support

Join us on our Corps of Discovery of the mind and heart. Help us bring hope and potential help to nano-rare patients today. For free, for life.

Follow us on social for updates on our latest efforts

Go to Top